


Biosimilars: Expanding Options for Patient Care

Extensive use of and growing demand for biologics come at a time when there is increasing need for savings and efficiencies for health care systems¹⁻⁶


1 Biosimilars are **highly similar in terms of safety and effectiveness** to an existing biologic medicine, with no clinically meaningful differences⁷



2 Biosimilars are **much more complex** than small molecules and are created in living systems that require significant expertise and state-of-the-art technology⁸⁻¹¹




3 Biosimilars are evaluated in **rigorous analytical, nonclinical, and clinical studies** to be licensed by the FDA^{7,12}



The need for comparative clinical data will be evaluated on a case-by-case basis depending on residual uncertainty

4 Biosimilars may offer **additional treatment options** that may increase savings and efficiencies to health care systems and expand the use of biologic therapies, which may lead to better overall health outcomes¹³⁻¹⁵



- ✓ Expanded options
- ✓ Increased use of biologics
- ✓ Potential savings

5 Pfizer Biosimilars expands **Pfizer's commitment to provide therapies that may improve the lives of patients**, leveraging our global presence and expertise to deliver high-quality biosimilars¹⁶⁻¹⁹



References

1. Schumock GT, Li EC, Suda KJ, et al. National trends in prescription drug expenditures and projections for 2015. *Am J Health Syst Pharm.* 2015;72(9):717-736.
2. Long D. IMS Health. Perspectives on the evolving biosimilars landscape. Presented at: HDMA Distribution Management Conference and Expo. Orlando, FL; March 8-11, 2015.
3. IMS Institute for Healthcare Informatics. Global Outlook for Medicines Through 2018. November 2014. Parsippany, NJ: IMS Health Incorporated; 2014.
4. Centers for Medicare & Medicaid Services. *NHE Projections 2014-2024*. <https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/NationalHealthExpendData/NationalHealthAccountsProjected.html>. Accessed December 30, 2015.
5. US Food and Drug Administration (FDA). *New Molecular Entity and New Therapeutic Biological Product Approvals for 2015*. <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugInnovation/ucm430302.htm>. Accessed December 30, 2015.
6. Express Scripts. *Specialty Drug Spending to Jump 67% by 2015*. <http://lab.express-scripts.com/insights/specialty-medications/specialty-drug-spending-to-jump-67-percent-by-2015>. Accessed July 20, 2016.
7. US Food and Drug Administration. *Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product*. Silver Spring, MD: FDA; 2015.
8. Elgert KD. Antibody structure and function. In: Elgert KD, ed. *Immunology: Understanding the Immune System*. Hoboken, NJ: Wiley & Sons, Inc.; 1998:58-78.
9. Kozlowski S, Woodcock J, Midthun K, Sherman RB. Developing the nation's biosimilars program. *N Engl J Med.* 2011;365(5):385-388.
10. Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. *Ann Oncol.* 2008;19(3):411-419.
11. US Food and Drug Administration (FDA). *Abbreviated New Drug Application (ANDA): Generics*. July 14, 2015. <http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/AbbreviatedNewDrugApplicationANDAGenerics/>. Accessed January 3, 2016.
12. Schneider CK, Vlemminckx C, Gravanis I, et al. Setting the stage for biosimilar monoclonal antibodies. *Nat Biotechnol.* 2012;30(12):1179-1185.
13. Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology—"O brave new world." *Nat Rev Rheumatol.* 2012;8(7):430-436.
14. Henry D, Taylor C. Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars. *Semin Oncol.* 2014;41(suppl 3):S13-S20.
15. Strober BE, Armour K, Romiti R, et al. Biopharmaceuticals and biosimilars in psoriasis: what the dermatologist needs to know. *J Am Acad Dermatol.* 2012;66(2):317-322.
16. Data on File. Pfizer Inc, New York, NY.
17. Pfizer 2015 Annual Review. *Manufacturing and Supply Chain*. https://www.pfizer.com/files/investors/financial_reports/annual_reports/2015/manufacturing-and-supply-chain.htm. Accessed July 20, 2016.
18. Hodgson J. WHO guidelines presage US biosimilars legislation? *Nat Biotechnol.* 2009;27(11):963-965.
19. Pfizer Inc. Pfizer Pipeline. February 2, 2016. http://www.pfizer.com/sites/default/files/product-pipeline/Produce_Pipeline_Update.pdf. Accessed August 8, 2016.